ERF and colorectal adenocarcinoma: Somatic loss‐of‐function mutations in ERF have been reported in tumors including prostate, stomach and colorectal adenocarcinomas and Ewing's sarcoma (Bose et al., 2017; Huang et al., 2017) at frequencies of 3–5%.